Cardiff Oncology (NASDAQ:CRDF) Trading 0.7% Higher

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDFGet Free Report) traded up 0.7% on Monday . The company traded as high as $3.07 and last traded at $2.95. 565,294 shares changed hands during trading, a decline of 55% from the average session volume of 1,242,739 shares. The stock had previously closed at $2.93.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Cardiff Oncology in a research note on Monday, May 6th. Piper Sandler upped their target price on shares of Cardiff Oncology from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st.

Check Out Our Latest Stock Analysis on Cardiff Oncology

Cardiff Oncology Price Performance

The company has a market capitalization of $131.92 million, a PE ratio of -3.28 and a beta of 1.89. The company’s 50 day simple moving average is $4.04 and its 200 day simple moving average is $2.92.

Cardiff Oncology (NASDAQ:CRDFGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.11 million. Cardiff Oncology had a negative net margin of 6,594.92% and a negative return on equity of 54.54%. On average, equities analysts forecast that Cardiff Oncology, Inc. will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Cardiff Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. purchased a new position in shares of Cardiff Oncology during the first quarter worth approximately $1,351,000. Vanguard Group Inc. grew its position in shares of Cardiff Oncology by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock worth $10,260,000 after acquiring an additional 9,468 shares during the last quarter. Blair William & Co. IL grew its position in shares of Cardiff Oncology by 32.4% during the first quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock worth $919,000 after acquiring an additional 42,180 shares during the last quarter. Callan Capital LLC grew its position in shares of Cardiff Oncology by 37.2% during the first quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock worth $228,000 after acquiring an additional 11,600 shares during the last quarter. Finally, PFG Investments LLC purchased a new position in shares of Cardiff Oncology during the first quarter worth approximately $53,000. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

About Cardiff Oncology

(Get Free Report)

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

See Also

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.